SURMOUNT-3

What is SURMOUNT-3?

Tirzepatide started after a 12-week intensive lifestyle lead-in (Wadden et al., Nature Medicine 2023): a further −18.4% on tirzepatide across the 72-week treatment phase, while the placebo group regained 2.5%.

Everyone had already lost at least 5% through lifestyle work, so the trial shows that success with lifestyle change did not make the drug redundant. It did not test coaching against no coaching, which is worth remembering when a seller bundles coaching and charges for it.

Related reading: SURMOUNT-3: Tirzepatide After a Lifestyle Run-In

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where SURMOUNT-3 comes up on this site

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers